Zynex (ZYXI)

• Market cap: $73.8M
• 1 day: -25.56%
• 5 days: -31.12%
• 1 month: -24.55%
• 3 months: -79.46%
• 6 months: -81.60%
• Year to date: -78.75%
• 1 year: -84.87%
• 5 years: -89.66%
• 10 years: -61.84%
• Sector: Healthcare
• Industry: Medical Distribution

About: Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.

Employees: 1,000

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

1.44% less ownership

Funds ownership: 26.8% [Q3] → 25.36% (-1.44%) [Q4]

4% less funds holding

Funds holding: 100 [Q3] → 96 (-4) [Q4]

7% less capital invested

Capital invested by funds: $69.4M [Q3] → $64.7M (-$4.71M) [Q4]

21% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 14

24% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 34

67% less call options, than puts

Call options by funds: $25K | Put options by funds: $76K

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4 141% upside
• Avg. target: $6 261% upside
• High target: $8 382% upside

2 analyst ratings

• positive: 1 50%
• neutral: 1 50%
• negative: 0 0%

RBC Capital Shagun Singh 49% 1-year accuracy 33 / 68 met price target	141% upside $4	Sector Perform Maintained	30 Apr 2025
HC Wainwright & Co. Yi Chen 33% 1-year accuracy 57 / 173 met price target	382% upside $8	Buy Maintained	30 Apr 2025